BofA Securities Maintains Arvinas(ARVN.US) With Buy Rating, Raises Target Price to $57
Analysts' Opinions Are Mixed on These Healthcare Stocks: Outset Medical (OM), Arvinas Holding Company (ARVN) and Innovent Biologics (OtherIVBXF)
Buy Rating for Arvinas Holding Company Driven by Vepdeg's Promising Potential and Market Opportunity
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $48
Express News | Guggenheim Reiterates Buy on Arvinasto Buy
Arvinas Down on Investors' Read of Lilly Data, Says BTIG
Revenues Not Telling The Story For Arvinas, Inc. (NASDAQ:ARVN) After Shares Rise 28%
